Moderna Stock News

Moderna Inc.'s stock soared 10% Tuesday to lead S&P 500 index gainers, after Oppenheimer upgraded the stock to the equivalent of buy and said it expects the biotech to have five products approved by 2

The vaccine maker's shares tumbled 45% over the past 12 months, but Oppenheimer analysts can see a turning point.

The general stock market is concluding 2023 on a positive note, propelled by specific equities that have spearheaded an end-of-year rally. Significantly, these gains have enabled several stocks to rec

In the latest trading session, Moderna (MRNA) closed at $99.45, marking a +0.67% move from the previous day.

The U.S. stock market staged a remarkable rally in 2023, but 173 stocks in the S&P 500 were still down for the year.

Merck and Moderna are teaming up to make an advanced oncology drug. The candidate's clinical trials are proceeding swimmingly.

The five worst performers in the market benchmark so far this year could be set for brighter futures.

A 2023 stock market recap is a tale of highs and lows. We entered the year after a Fed tightening cycle proved restrictive but seemingly unsuccessful as inflation continued while rates rose.

Covid-19-vaccine makers Moderna and Pfizer saw shares drop in 2023, but analysts expect double-digit-percentage gains next year.

With the possibility of an interest rate cut by the FED and fairly optimistic targets for the S&P 500 index by the largest analytical groups, investors might be looking for the best opportunities in t

CAMBRIDGE, MA / ACCESSWIRE / December 20, 2023 / Moderna, Inc. (Nasdaq:MRNA), today announced that Jamey Mock, Chief Financial Officer, will present at the 42nd annual J.P. Morgan Healthcare Conferenc

Investors need to understand and be able to steer clear of companies that have a poor future outlook. Whether from reduced financial guidance, overall financial instability, management issues, or rele

Is Moderna stock a buy after announcing promising results for its Merck-tied cancer vaccine? Is MRNA stock a buy right now?

BioNTech's pipeline should take center stage going forward. JD.com is dirt cheap after a big sell-off.

Investors have shied away from buying Moderna shares as demand for its coronavirus vaccine declines. But the biotech has set high goals, aiming to release many new products during the next few years.